Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | ETV6 | P41212 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.32 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.32 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3321417 | 0.89 | PDK2 (0.36) | L3MBTL1METHDAC2PDK2PSD | |
| SCHEMBL31115874 | 0.81 | MAPT (0.33) | L3MBTL1HDAC2PSDMAPTTDP1 | |
| SCHEMBL1197473 | 0.81 | L3MBTL1 (0.51) | L3MBTL1HDAC2NAMPTPRMT5WDR77 | |
| SCHEMBL1436338 | 0.81 | PSD (0.34) | L3MBTL1HDAC2PSD | |
| SCHEMBL13837589 | 0.81 | KIT (0.36) | KITL3MBTL1METHDAC2NAMPT | |
| SCHEMBL23541176 | 0.80 | EGLN3 (0.43) | L3MBTL1HDAC2PDK2MAPTTDP1 | |
| SCHEMBL5965015 | 0.79 | HTT (0.37) | L3MBTL1HDAC2PDK2HDAC1MAPT | |
| SCHEMBL26066445 | 0.78 | KDM4E (0.32) | L3MBTL1PSDMAPTTDP1 | |
| SCHEMBL177295 | 0.78 | L3MBTL1 (0.41) | L3MBTL1HDAC2HDAC1MAPTTDP1 | |
| SCHEMBL25962972 | 0.78 | HDAC3 (0.34) | HDAC2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117659010-A | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-111867581-B | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2023-12-26 | — | — | CN | disclosed |
| WO-2023154344-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154314-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-3204382-B1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-12-01 | — | — | EP | disclosed |
| EP-3204382-B1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-12-01 | — | — | EP | disclosed |
| CN-111867581-A | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| US-10253023-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-04-09 | — | — | US | disclosed |
| CN-101821257-A | 5-HT 7Receptor antagonist | LILLY CO ELI | 2010-09-01 | — | — | CN | disclosed |
| US-20100197700-A1 | 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2010-08-05 | — | — | US | disclosed |
| US-20100197700-A1 | 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2010-08-05 | — | — | US | disclosed |
| US-20100197700-A1 | 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2010-08-05 | — | — | US | disclosed |
| EP-2201002-A1 | 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20100120785-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-05-13 | — | — | US | disclosed |
| EP-2155717-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2009048765-A1 | 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009048765-A1 | 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2008141020-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253023-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | BTK, SYK, LYN | KIT 1188/4885L3MBTL1 1862/4885MET 2334/4885 |
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | KIT 1083/4885L3MBTL1 1551/4885MET 2708/4885 |
| US-20100197700-A1 | 5-HT7 RECEPTOR ANTAGONISTS | HTR7, HTR1A, HTR2C | KIT 120/4885L3MBTL1 4552/4885MET 561/4885 |
| US-20100120785-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | HTR7, HTR2C, HTR4 | KIT 184/4885L3MBTL1 4103/4885MET 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.